Florbetapir (F18‐AV‐45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging
Open accessAbstract
OBJECTIVE: To evaluate the performance characteristics of florbetapir F18 positron emission tomography (PET) in patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and healthy control subjects (HCs). METHODS: Florbetapir PET was acquired in 184 subjects (45 AD patients, 60 MCI patients, and 79 HCs) within a multicenter phase 2 study. Amyloid burden was assessed visually and quantitatively, and was classified as positive or negative. RESULTS: Florbetapir PET was rated visually amyloid positive in 76% of AD patients, 38% of MCI patients, and 14% of HCs. Eighty-four percent of AD patients, 45% of MCI patients, and 23% of HCs were classified as amyloid positive using a quantitative threshold. Amyloid positivity and mean cortical amyloid burden were associated with age and apolipoprotein E ε4 carrier status. CONCLUSIONS: : The data are consistent with expected rates of amyloid positivity among individuals with clinical diagnoses of AD and MCI, and indicate the potential value of florbetapir F18 PET as an adjunct to clinical diagnosis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A similar proportion of individuals clinically diagnosed as AD dementia have normal amyloid PET or CSF Aβ42 studies.
“and a similar proportion has normal amyloid PET or CSF Aβ42 studies [53–62].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589 · see citing works
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 2× · see citing works
“Indeed, investigators have recently proposed revised diagnostic criteria that are based, in part, on biomarker evidence of AD pathology, even in individuals withmildmemory impairmentwho are not sufficiently impaired to meet criteria for dementia [19–22].”
BackgroundMoms, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., Mellits, E. D., & Clark, C. (1989) · Neurology · doi:10.1212/wnl.39.9.1159 · Cited by 4,130 · see citing works
Self-citationCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works
Self-citationReiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785 · see citing works
Self-citationWong, D. F., Rosenberg, P. B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H. T., Dannals, R. F., Nandi, A., Brašić, J. R., Ye, W., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069088 · Cited by 684 · see citing works
Self-citationMild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions
Bennett, D. A., Schneider, J. A., Bienias, J. L., Evans, D. A., & Wilson, R. S. (2005) · Neurology · doi:10.1212/01.wnl.0000152982.47274.9e · Cited by 537 · see citing works
Diagnostic Criteria for Neuropathologic Assessment of Alzheimer’s Disease
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00062-6 · Cited by 410 · see citing works
“Preclinical” AD revisited: Neuropathology of cognitively normal older adults
Schmitt, F. A., Davis, D. G., Wekstein, D. R., Smith, C. D., Ashford, J. W., & Markesbery, W. R. (2000) · Neurology · doi:10.1212/wnl.55.3.370 · Cited by 369 · see citing works
HULETTE, C. M., WELSH-BOHMER, K. A., MURRAY, M. G., SAUNDERS, A. M., MASH, D. C., & MCINTYRE, L. M. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199812000-00009 · Cited by 311 · see citing works
Leinonen, V. (2008) · Archives of Neurology · doi:10.1001/archneur.65.10.noc80013 · Cited by 199 · see citing works
Flagged first, then by citations
Research works printed but not linked: 35
- [1]Aizenstein HJ Nebes RD Saxton JA Price JC Mathis CA Tsopelas ND Ziolko SK James JA Snitz BE Houck PR Frequent amyloid deposition without significant cognitive impairment among the elderly Arch. Neurol 2008 65 1509 1517 Aizenstein 2008 19001171 PMC2636844
- [2]Becker JA, Hedden T Carmasin J Maye J Rentz DM Putcha D Fischl B Greve D Marshall G Salloway S Marks D Buckner RL Sperling RA Johnson KA Amyloid-Associated Cortical Thinning in Clinically Normal Elderly Annals of Neurology 2010 PMC3117980 21437929
- [3]Bacskai BJ Frosch MP Freeman SH Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case re port Arch Neurol 2007 64 431 434 17353389
- [6]Choi SR Golding G Zhuang Z Preclinical properties of 18F-AV-45: a PET agent for Aβ plaques in the brain J Nucl Med 2009 50 1887 94 19837759 PMC3065020
- [7]Clark CM Schneider JA Bedell BJ Use of florbetapir-PET for imaging β-amyloid pathology JAMA 2011 305 3 275 283 21245183 PMC7041965
- [8]Dubois B Feldman HH Jacova C Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS–ADRDA GlaxoSmithKline, Janssen, Lilly, Lundbeck, Medivation, Merck, Merz, criteria Lancet Neurol 2007 6 734 46 17616482
- [9]Dubois B Revising the definition of Alzheimer’s disease: a new lexicon Lancet Neurology 2010 9 1118 20934914
- [10]Engler H Forsberg A Almkvist O Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease Brain 2006 129 2856 2866 16854944
- [11]Fagan AM Roe CM Xiong C Mintun MA Morris JC Holtzman DM Cerebrospinal fl uid tau/β-amyloid ratio as a prediction of cognitive decline in nondemented older adults Arch Neurol 2007 64 343 49 17210801
- [12]Folstein MF Folstein SE McHugh PR Mini-Mental State: a prac tical method for grading the cognitive state of patients for the clinician J Psychiatr Res 1975 12 189 198 1202204
- [13]Forsberg A Engler H Almkvist O PET imaging of amyloid deposition in patients with mild cognitive impairment Neurobiol Aging 2008 29 1456 1465 17499392
- [14]Gomperts SN Rentz DM Moran E Becker JA Locascio JJ Klunk WE Mathis CA Elmaleh DR Shoup T Fischman AJ Imaging amyloid deposition in Lewy body diseases Neurology 2008 71 903 910 18794492 PMC2637553
- [16]Hyman 1997 Hyman BT The neuropathological diagnosis of Alzheimer’s disease: clinical-pathological studies Neurobiol Aging 1997 18 S27 32 9330982
- [17]Ikonomovic MD Klunk WE Abrahamson EE Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease Brain 2008 131 1630 45 18339640 PMC2408940
- [18]Jack CR Lowe VJ Weigand SD Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease Brain 2009 132 1355 1365 19339253 PMC2677798
- [19]Joshi AD Pontecorvo MJ Clark CM Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer’s Disease and Cognitively Normal Subjects J Nucl Med 2012 53 378 384 22331215
- [20]Klunk WE Engler H Nordberg A Wang Y Blomqvist G Holt DP Bergstrom M Savitcheva I Huang GF Estrada S Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B Ann. Neurol 2004 55 306 319 14991808
- [21]Knopman DS Parisi JE Salviati A Neuropathology of cognitively normal elderly J Neuropathol Exp Neurol 2003 62 11 1087 1095 14656067
- [22]Levine Walker Molecular polymorphism of Abeta in Alzheimer’s disease Neurobiol Aging 2008 PMC2842206 18619711
- [23]McKhann G Drachman D Folstein M Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease Neurology 1984 34 939 944 6610841
- [25]Morris JC The Clinical Dementia Rating Scale (CDR): Current version and scoring rules Neurology 1993 43 2412 2414 8232972
- [27]Okello A Koivunen J Edison P Conversion of amyloid positive and negative MCI to AD over 3 years: an C-PIB PET study Neurology 2009 73 754 60 19587325 PMC2830881
- [28]Pearl GS Diagnosis of Alzheimer’s disease in a community hospital-based brain bank program Southern Medical Journal 1997 90 7 720 723 9225895
- [29]Petersen RC Parisi JE Dickson DW Neuropathologic features of amnestic mild cognitive impairment Arch Neurol 2006 63 5 665 672 16682536
- [30]Pike KE Savage G Villemagne VL Ng S Moss SA Maruff P Mathis CA Klunk WE Masters CL Rowe CC Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease Brain 2007 130 2837 2844 17928318
- [31]Price JL Morris JC Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease Ann Neurol 1999 45 3 358 368 10072051
- [32]Rentz DM Locascio JJ Becker JA Moran EK Eng E Buckner RL Sperling RA Johnson KA Cognition, reserve, and amyloid deposition in normal aging Ann. Neurol 2010 67 353 364 20373347 PMC3074985
- [33]Rinne JO Brooks DJ Rossor MN 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study Lancet Neurol 2010 9 363 372 20189881
- [34]Rowe CC Ellis KA Rimajova M Bourgeat P Pike KE Jones G Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging Neurobiol Aging 2010 31 1275 83 20472326
- [35]Rosen Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer’s disease Acta Neuropathol 2010 119 221 33 19690877 PMC3045810
- [36]Rosen WG Mohs RC Davis KL A new rating scale for Alzheimer’s disease The American Journal of Psychiatry 1984 141 1356 1364 6496779
- [39]Sperling RA Laviolette PS O’Keefe K Amyloid deposition is associated with impaired default network function in older per sons without dementia Neuron 2009 63 178 188 19640477 PMC2738994
- [42]Weintraub S The record of independent daily living: an informant completed measure of activities of daily living and behavior in elderly patients with cognitive impairment The American Journal of Alzheimer’s Disease and Other Dementias 1986 1 35 39
- [43]Wolk DA Price JC Saxton JA Snitz BE James JA Lopez OL Amyloid imaging in mild cognitive impairment subtypes Ann Neurol 2009 65 557 68 19475670 PMC2828870
- [45]Yesavage JA Brink TL Rose TL Lum O Huang V Adey M Leirer VO Development and validation of a geriatric depression screening scale Journal of Psychiatric Research 1983 17 37 49 7183759
Cited by
Sorted by citations
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · see citing works
Self-citationThe Diagnosis and Management of Mild Cognitive Impairment: A Clinical Review
Langa, K. M., & Levine, D. A. (2014) · JAMA · doi:10.1001/jama.2014.13806 · Cited by 1,337 · see citing works
Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.002 · Cited by 603 · see citing works
Self-citationTrial of solanezumab in preclinical Alzheimer's disease
Sperling, R. A., Donohue, M. C., Raman, R., Rafii, M. S., Johnson, K., Masters, C. L., van Dyck, C. H., Iwatsubo, T., Marshall, G. A., Yaari, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2305032 · Cited by 429 · see citing works
Self-citationJack, C. R., Therneau, T. M., Weigand, S. D., Wiste, H. J., Knopman, D. S., Vemuri, P., Lowe, V. J., Mielke, M. M., Roberts, R. O., Machulda, M. M., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1971 · Cited by 300 · see citing works
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum
Jansen, W. J., Janssen, O., Tijms, B. M., Vos, S. J. B., Ossenkoppele, R., Visser, P. J., Amyloid Biomarker Study Group, Aarsland, D., Alcolea, D., Altomare, D., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.5216 · Cited by 290 · see citing works
Self-citationPontecorvo, M. J., Devous, M. D., Kennedy, I., Navitsky, M., Lu, M., Galante, N., Salloway, S., Doraiswamy, P. M., Southekal, S., Arora, A. K., et al. (2019) · Brain · doi:10.1093/brain/awz090 · Cited by 249 · see citing works
Self-citationPET/SPECT imaging agents for neurodegenerative diseases
Zhu, L., Ploessl, K., & Kung, H. F. (2014) · Chem. Soc. Rev. · doi:10.1039/c3cs60430f · Cited by 185 · see citing works
Serrano‐Pozo, A., Qian, J., Monsell, S. E., Betensky, R. A., & Hyman, B. T. (2015) · Annals of Neurology · doi:10.1002/ana.24369 · Cited by 176 · see citing works
Amyloid-β <sup>11</sup> C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials
Liu, E., Schmidt, M. E., Margolin, R., Sperling, R., Koeppe, R., Mason, N. S., Klunk, W. E., Mathis, C. A., Salloway, S., Fox, N. C., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001877 · Cited by 151 · see citing works
Self-citationMild to moderate Alzheimer dementia with insufficient neuropathological changes
Serrano‐Pozo, A., Qian, J., Monsell, S. E., Blacker, D., Gómez‐Isla, T., Betensky, R. A., Growdon, J. H., Johnson, K. A., Frosch, M. P., Sperling, R. A., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24125 · Cited by 120 · see citing works
Self-citationMonsell, S. E., Kukull, W. A., Roher, A. E., Maarouf, C. L., Serrano, G., Beach, T. G., Caselli, R. J., Montine, T. J., & Reiman, E. M. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1721 · Cited by 82 · see citing works
Self-citationLista, S., Molinuevo, J. L., Cavedo, E., Rami, L., Amouyel, P., Teipel, S. J., Garaci, F., Toschi, N., Habert, M.-O., Blennow, K., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150202 · Cited by 53 · see citing works
Wang, Y., Sun, Y., Wang, Y., Jia, S., Qiao, Y., Zhou, Z., Shao, W., Zhang, X., Guo, J., Zhang, B., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01324-4 · Cited by 34 · see citing works
“A biomarker, aggregated Aβ or related pathologic state, could be evaluated by amyloid positron emission tomography (PET) or CSF Aβ 42 or Aβ 42 /Aβ 40 ratio [9].”
BackgroundNirogi, R., Ieni, J., Goyal, V. K., Ravula, J., Jetta, S., Shinde, A., Jayarajan, P., Benade, V., Palacharla, V. R. C., Dogiparti, D. K., et al. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12307 · Cited by 29 · see citing works
Deep-Learning Based Multi-Modal Models for Brain Age, Cognition and Amyloid Pathology Prediction
Wang, C., Zhang, W., Ni, M., Wang, Q., Liu, C., Dai, L., Zhang, M., Shen, Y., & Gao, F. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-025-01773-z · Cited by 11 · see citing works
- Authors
- Johnson, K. A., Sperling, R. A., Gidicsin, C. M., Carmasin, J. S., Maye, J. E., Coleman, R. E., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., Fleisher, A. S., Murali Doraiswamy, P., Carpenter, A. P., Clark, C. M., Joshi, A. D., Lu, M., Grundman, M., Mintun, M. A., Pontecorvo, M. J., Skovronsky, D. M., & AV45‐A11 study group
- Affiliations
- Harvard University (US)
- Duke Medical Center (US)
- Banner Alzheimer’s Institute (US)
- Banner Sun Health Research Institute (US)
- Nova Southeastern University (US)
- University of California San Diego (US)
- Duke University Medical Center Durham NC USA
- Avid Radiopharmaceuticals (United States) (US)
- Avid Radiopharmaceuticals Philadelphia PA USA
- Corresponding author
- Johnson, Keith A.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2013-02
- Volume
- 9
- Issue
- 5S
- Pages
- S72-83
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC3800236
- OpenAlex
- W2079436233
- Cited by
- 270
- References
- 12
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 7 · 2023: 23 · 2022: 19 · 2021: 23 · 2020: 38 · 2019: 22 · 2018: 17 · 2017: 14 · 2016: 23 · 2015: 23 · 2014: 20 · 2013: 9
- FWCI
- 17.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01AG027435, R01AG037497, P30AG019610, P50AG005134, P01AG004953)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- florbetapir, amyloid PET
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alzheimer Disease, Aniline Compounds, Female, Fluorine Radioisotopes, Humans, Male, Mental Status Schedule, Middle Aged, Stilbenes, Positron-Emission Tomography, Apolipoprotein E4, Amyloidogenic Proteins, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
